biotech & health insights
🧬 Biotech News — August 28, 2026
Celularity Surges 139% as New Jersey Manufacturing Deal Targets $300 Million in Purchase Orders
Biotechnology stocks delivered another highly active session as investors responded to manufacturing partnerships, clinical-trial data, oncology developments, financing transactions and Nasdaq compliance measures.
Celularity was the standout mover, soaring 139% after establishing a domestic manufacturing partnership expected to generate more than $300 million in cumulative purchase orders. Meanwhile, Kazia Therapeutics and HCW Biologics advanced on encouraging clinical and translational data, while several smaller biotechnology companies announced reverse stock splits aimed at maintaining exchange compliance.
🚀 Celularity (NASDAQ: CELU) — +139% | $2.10
Celularity shares exploded higher after the company established a domestic manufacturing partnership with MuseCell Innovations to begin production of Dezawa MuseCells and derived exosome products at Celularity’s New Jersey facility.
The long-term agreement is estimated to generate more than $300 million in cumulative purchase orders and is expected to create approximately 200 high-tech jobs over the next five years.
The agreement represents a significant potential commercial opportunity for Celularity while also expanding domestic manufacturing capabilities for MuseCell-related products.
📈 Shares closed: $2.10
🟢 Daily move: +139%
💰 Potential cumulative purchase orders: >$300 million
👥 Expected jobs: ~200 over five years
🏭 Manufacturing location: New Jersey
Investor takeaway: The size of the potential purchase-order commitment makes the partnership a major commercial catalyst and was clearly the dominant driver of today’s share-price reaction.
🧪 Kazia Therapeutics (NASDAQ: KZIA) — +16% | $16.90
Kazia Therapeutics released initial Phase 1b clinical data from six evaluable patients with advanced triple-negative breast cancer (TNBC) evaluating paxalisib.
The company reported a 100% clinical benefit rate and an 83% objective response rate among the evaluable patients. No serious adverse events were attributed to paxalisib.
Translational analyses also showed significant reductions in circulating tumor-cell (CTC) clusters and exhausted CD8+ T cells as the study progresses.
The trial remains in development, with the company targeting full enrollment by July 2027.
📈 Shares closed: $16.90
🟢 Daily move: +16%
🎯 Clinical benefit rate: 100%
📊 Objective response rate: 83%
👥 Evaluable patients: 6
📅 Target full enrollment: July 2027
Investor takeaway: The early data are encouraging, but the very small evaluable population means substantially more clinical evidence will be needed to establish paxalisib’s efficacy and durability.
🧬 HCW Biologics (NASDAQ: HCWB) — +17% | $3.17
HCW Biologics presented preclinical and human data supporting its IL-15 fusion and TGF-β trap platform.
The technology is being incorporated into next-generation TRBC-based checkpoint inhibitors and T-cell engagers, including HCW11-040 and HCW11-018b.
Both programs are currently in IND-enabling development, with clinical trial starts projected for 2027.
📈 Shares closed: $3.17
🟢 Daily move: +17%
🧬 Key programs: HCW11-040 and HCW11-018b
🔬 Current stage: IND-enabling development
📅 Projected clinical starts: 2027
Investor takeaway: The company’s platform remains early stage, but the latest data provide additional support for its strategy of combining immune-cell activation with checkpoint and T-cell-engager approaches.
💵 Moderna (NASDAQ: MRNA) — -5% | $142.77
Moderna announced a $2.0 billion private placement of convertible senior notes maturing in 2032.
The financing is designed to increase the company’s long-term capital flexibility as Moderna continues scaling its mRNA vaccine portfolio and advancing its oncology development programs.
Despite the substantial capital raise, Moderna shares declined 5% during the session.
📉 Shares closed: $142.77
🔴 Daily move: -5%
💰 Convertible notes: $2.0 billion
📅 Maturity: 2032
Investor takeaway: The transaction provides significant financial flexibility, although convertible financing can introduce future dilution depending on the terms and eventual conversion of the notes.
🔄 Artelo Biosciences (NASDAQ: ARTL) — -7% | $0.66
Artelo Biosciences announced a 1-for-9 reverse stock split, effective August 31, 2026.
The company said the action is intended to strengthen its share price, liquidity and overall marketability.
Following the consolidation, outstanding common stock is expected to fall to approximately 547,774 shares, with warrants and derivatives adjusted proportionately according to their governing terms.
📉 Shares closed: $0.66
🔴 Daily move: -7%
🔄 Reverse split: 1-for-9
📅 Effective date: August 31, 2026
📊 Post-split shares: ~547,774
Investor takeaway: The reverse split is primarily a capital-markets measure and does not itself change the underlying value of the company’s business or pipeline.
📉 GlucoTrack (NASDAQ: GCTK) — -11% | $0.29
GlucoTrack announced a 1-for-15 reverse stock split, also scheduled to become effective on August 31, 2026.
The move is intended to help the company regain compliance with Nasdaq’s minimum bid-price requirement.
The transaction will reduce outstanding common stock to approximately 798,144 shares, while the company will retain its existing ticker symbol.
📉 Shares closed: $0.29
🔴 Daily move: -11%
🔄 Reverse split: 1-for-15
📅 Effective date: August 31, 2026
📊 Post-split shares: ~798,144
Investor takeaway: The reverse split addresses a listing requirement but also highlights the pressure that prolonged weakness in the share price can place on smaller biotechnology companies.
🏥 CalciMedica (NASDAQ: CALC) — -10% | $4.75
CalciMedica announced a reverse stock split designed to restore compliance with Nasdaq’s minimum bid-price requirement and protect the company’s continued listing status.
Shares declined 10% during the session.
📉 Shares closed: $4.75
🔴 Daily move: -10%
🔄 Corporate action: Reverse stock split
🎯 Objective: Nasdaq minimum bid-price compliance
Investor takeaway: Maintaining exchange compliance remains an important near-term priority, although the reverse split itself does not change the company’s fundamental clinical prospects.
💰 Addex Therapeutics (NASDAQ: ADXN) — -9% | $3.85
Addex Therapeutics raised approximately $2.8 million through its ATM program with H.C. Wainwright.
The company sold 437,869 ADSs representing 52.5 million shares, extending its expected cash runway through Q4 2027.
However, the financing also increases the company’s share count, with outstanding shares rising to approximately 210.3 million.
📉 Shares closed: $3.85
🔴 Daily move: -9%
💵 Capital raised: $2.8 million
📊 ADSs sold: 437,869
📈 Shares represented: 52.5 million
📅 Cash runway: Q4 2027
Investor takeaway: Addex gains additional financial runway, but the financing highlights the familiar biotech trade-off between extending operations and increasing shareholder dilution.
🔬 Key Biotech Themes
🏭 Commercial Manufacturing Emerges as a Major Catalyst
Celularity’s partnership with MuseCell Innovations dominated the session, demonstrating how commercial contracts and manufacturing commitments can create powerful catalysts for small-cap biotech companies.
The potential for more than $300 million in cumulative purchase orders and approximately 200 new high-tech positions gives investors a tangible commercial component beyond clinical development.
🧪 Early Clinical Data Continue to Drive Volatility
Kazia’s initial TNBC results generated a strong positive response after the company reported high clinical benefit and objective response rates.
However, the data come from only six evaluable patients, making future enrollment and additional clinical follow-up critical.
💵 Financing Remains a Central Issue
Moderna’s $2 billion convertible-note financing illustrates how even larger biotechnology companies continue to prioritize balance-sheet flexibility.
For smaller companies such as Addex, capital raises can provide essential runway but also create meaningful dilution concerns.
⚠️ Nasdaq Compliance Remains a Challenge for Small Biotech
Artelo Biosciences, GlucoTrack and CalciMedica all turned to reverse-stock-split measures aimed at addressing listing requirements.
These actions can provide companies with additional time to satisfy exchange requirements, but investors should distinguish between technical share-price adjustments and genuine improvements in business fundamentals.
📊 Biotech Movers at a Glance
| Company | Ticker | Key Catalyst | Close | Move |
|---|---|---|---|---|
| Celularity | CELU | MuseCell manufacturing partnership | $2.10 | 🟢 +139% |
| Kazia Therapeutics | KZIA | Phase 1b TNBC data | $16.90 | 🟢 +16% |
| HCW Biologics | HCWB | Platform data and pipeline update | $3.17 | 🟢 +17% |
| Moderna | MRNA | $2B convertible-note financing | $142.77 | 🔴 -5% |
| Artelo Biosciences | ARTL | 1-for-9 reverse split | $0.66 | 🔴 -7% |
| GlucoTrack | GCTK | 1-for-15 reverse split | $0.29 | 🔴 -11% |
| CalciMedica | CALC | Reverse split for Nasdaq compliance | $4.75 | 🔴 -10% |
| Addex Therapeutics | ADXN | $2.8M ATM financing | $3.85 | 🔴 -9% |
🔎 What Investors Should Watch Next
🧬 Celularity: Execution of the MuseCell manufacturing agreement and development of the anticipated purchase-order opportunity.
🧪 Kazia Therapeutics: Additional patient enrollment and clinical data as the Phase 1b program advances toward its July 2027 enrollment target.
🧬 HCW Biologics: IND-enabling progress for HCW11-040 and HCW11-018b ahead of potential clinical starts in 2027.
💵 Moderna: Deployment of its new capital across vaccines and oncology while investors assess the implications of convertible financing.
🔄 Artelo, GlucoTrack and CalciMedica: Nasdaq compliance and the impact of their respective reverse-stock-split actions.
💰 Addex Therapeutics: Use of newly raised capital and progress toward the company’s extended Q4 2027 cash runway.
🧬 Bottom Line
Today’s biotech market was dominated by a dramatic 139% surge in Celularity, following a manufacturing partnership with MuseCell Innovations that could generate more than $300 million in cumulative purchase orders and create approximately 200 high-tech jobs.
Kazia Therapeutics and HCW Biologics also gained momentum from clinical and platform updates, while Moderna strengthened its long-term financial flexibility through a $2 billion convertible-note transaction.
On the risk side, Artelo Biosciences, GlucoTrack and CalciMedica turned to reverse stock splits to address Nasdaq listing requirements, while Addex Therapeutics extended its cash runway through additional equity issuance.
The broader takeaway is clear: biotech investors continue to reward commercial validation, credible clinical progress and financial strength, while financing needs, dilution and exchange-compliance issues remain important risks across the sector.
